VYGR vs. CCCC, EDIT, TSHA, ADPT, ALLO, ALEC, ITOS, LXEO, FATE, and PROK
Should you be buying Voyager Therapeutics stock or one of its competitors? The main competitors of Voyager Therapeutics include C4 Therapeutics (CCCC), Editas Medicine (EDIT), Taysha Gene Therapies (TSHA), Adaptive Biotechnologies (ADPT), Allogene Therapeutics (ALLO), Alector (ALEC), iTeos Therapeutics (ITOS), Lexeo Therapeutics (LXEO), Fate Therapeutics (FATE), and ProKidney (PROK). These companies are all part of the "biological products, except diagnostic" industry.
C4 Therapeutics (NASDAQ:CCCC) and Voyager Therapeutics (NASDAQ:VYGR) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their dividends, institutional ownership, community ranking, media sentiment, earnings, analyst recommendations, risk, profitability and valuation.
C4 Therapeutics presently has a consensus price target of $10.11, indicating a potential upside of 78.01%. Voyager Therapeutics has a consensus price target of $18.00, indicating a potential upside of 113.52%. Given C4 Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Voyager Therapeutics is more favorable than C4 Therapeutics.
Voyager Therapeutics has higher revenue and earnings than C4 Therapeutics. Voyager Therapeutics is trading at a lower price-to-earnings ratio than C4 Therapeutics, indicating that it is currently the more affordable of the two stocks.
C4 Therapeutics has a beta of 3.22, meaning that its share price is 222% more volatile than the S&P 500. Comparatively, Voyager Therapeutics has a beta of 0.98, meaning that its share price is 2% less volatile than the S&P 500.
Voyager Therapeutics received 354 more outperform votes than C4 Therapeutics when rated by MarketBeat users. Likewise, 67.32% of users gave Voyager Therapeutics an outperform vote while only 37.88% of users gave C4 Therapeutics an outperform vote.
78.8% of C4 Therapeutics shares are held by institutional investors. Comparatively, 48.0% of Voyager Therapeutics shares are held by institutional investors. 8.0% of C4 Therapeutics shares are held by insiders. Comparatively, 4.7% of Voyager Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.
Voyager Therapeutics has a net margin of -2.56% compared to Voyager Therapeutics' net margin of -629.24%. C4 Therapeutics' return on equity of -1.28% beat Voyager Therapeutics' return on equity.
In the previous week, Voyager Therapeutics had 16 more articles in the media than C4 Therapeutics. MarketBeat recorded 26 mentions for Voyager Therapeutics and 10 mentions for C4 Therapeutics. Voyager Therapeutics' average media sentiment score of 0.47 beat C4 Therapeutics' score of 0.40 indicating that C4 Therapeutics is being referred to more favorably in the media.
Summary
Voyager Therapeutics beats C4 Therapeutics on 12 of the 18 factors compared between the two stocks.
This chart shows the number of new MarketBeat users adding VYGR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Voyager Therapeutics Competitors List
Related Companies and Tools
